New numbing shot could cut opioid use after nose jobs

NCT ID NCT05964868

ENROLLING_BY_INVITATION Symptom relief Sponsor: Jessyka Lighthall Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a long-acting numbing medication (liposomal bupivacaine) can better control pain after septorhinoplasty (nose surgery) compared to standard numbing drugs or a placebo. About 72 adults having nose surgery will receive one of three treatments at the end of their operation. Researchers will measure how much pain medication participants need and their reported pain levels. The goal is to see if this longer-lasting numbing agent can reduce opioid use and improve recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: liposomal bupivacaine (EXPAREL®)
What this could lead to: If it works, this could offer a longer-lasting pain relief option after nose surgery, potentially reducing the need for opioid painkillers.
What could go wrong: This is a single, small trial (72 people) testing a drug already used for other surgeries. The benefit may be small or not apply to all patients, and any new drug carries risks like allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAIN MANAGEMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

agnosia Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PAIN MANAGEMENT RHINOPLASTY

Contacts and locations

Locations

Jessyka Lighthall

Hershey, Pennsylvania, 17033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.